Koers Myrexis, Inc. Other OTC
Aandelen
MYRX
US62856H1077
Biotechnologie & Medisch Onderzoek
Omzet 2012 | - | Omzet 2013 | - | Marktkapitalisatie | 2,59 mln. 2,42 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2012 | -31 mln. -29,03 mln. | Nettowinst (verlies) 2013 | -11 mln. -10,3 mln. | EV/omzet 2012 | - |
Nettoliquiditeiten 2012 | 89,38 83,7 | Nettoliquiditeiten 2013 | 1,21 1,13 | EV/omzet 2013 | - |
K/w-verhouding 2012 |
-2,21
x | K/w-verhouding 2013 |
-0,19
x | Werknemers | - |
Dividendrendement 2012 * |
-
| Dividendrendement 2013 |
-
| Vrij verhandelbaar | 100% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Chief Executive Officer | 54 | 22-01-13 | |
Gary S. Mather
PRN | Corporate Officer/Principal | - | 01-01-01 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Chief Executive Officer | 54 | 22-01-13 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+16,49% | 122 mld. | |
+21,73% | 116 mld. | |
+22,18% | 27,03 mld. | |
-21,81% | 20,36 mld. | |
-16,89% | 16,43 mld. | |
-18,81% | 15,91 mld. | |
-44,74% | 15,6 mld. | |
+62,72% | 14,94 mld. | |
+3,09% | 13,59 mld. |